RBF Capital LLC Trims Stake in Teva Pharmaceutical Industries Ltd. $TEVA

RBF Capital LLC lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 60.0% during the 1st quarter, HoldingsChannel reports. The firm owned 20,000 shares of the company’s stock after selling 30,000 shares during the period. RBF Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $602,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc increased its position in shares of Teva Pharmaceutical Industries by 6.8% during the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock worth $112,618,000 after purchasing an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Teva Pharmaceutical Industries by 8.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock valued at $33,506,000 after purchasing an additional 80,106 shares in the last quarter. Norges Bank acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $1,098,060,000. TD Asset Management Inc grew its holdings in shares of Teva Pharmaceutical Industries by 47.1% during the fourth quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after buying an additional 118,075 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $9,126,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,493 shares of company stock valued at $10,537,510 over the last ninety days. Company insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research reports. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported second-quarter revenue of approximately $4.14 billion, ahead of consensus estimates of $4.02 billion. Innovative medicines grew 43% year over year in local-currency terms, helping offset weaker generics sales. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: Management raised its 2026 revenue outlook to $16.5 billion-$16.9 billion and increased projections for its three key innovative brands, signaling confidence in the company’s branded-drug growth strategy. Teva Outlines Higher 2026 Revenue Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting optimism about its long-acting injectable portfolio. UZEDY Record Q2 Net Sales
• Positive Sentiment: Piper Sandler reportedly forecast substantial potential appreciation for TEVA, adding to bullish sentiment following the results. Piper Sandler Forecasts Strong Price Appreciation
• Neutral Sentiment: Options activity was unusually elevated: traders bought about 23,688 calls on Wednesday, followed by roughly 27,659 puts on Thursday. The activity indicates heightened speculation but does not establish a clear directional signal. Unusually Large Options Trading
• Negative Sentiment: Second-quarter EPS of $0.02 missed the $0.08 consensus estimate, while acquisition-related costs and impairment charges contributed to a reported net loss of $576 million. Full-year EPS guidance of $1.91-$2.11 also remains below the $2.17 consensus estimate. Teva Q2 Earnings Lag Estimates

Teva Pharmaceutical Industries Stock Up 2.1%

NYSE TEVA opened at $35.45 on Friday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The business’s fifty day simple moving average is $33.22 and its 200-day simple moving average is $32.72. The firm has a market cap of $40.76 billion, a PE ratio of 59.09, a P/E/G ratio of 3.67 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.59%. The firm had revenue of $4.14 billion for the quarter. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.